Vinblastine-sulfate-Vincaleukoblastine-sulfate-salt-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEVinblastine sulfateCat. No.: HY-13780CAS No.: 143-67-9Synonyms: Vincaleukoblastine sulfate salt分式: CHNOS分量: 909.05作靶點(diǎn): Microtubule/Tubulin; Autophagy作通路: Cell Cycle/DNA Damage; Cytoskeleton; Autophagy儲(chǔ)存式: 4C, protect from light*

2、 In solvent : -80C, 6 months; -20C, 1 month (protect fromlight)溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 44 mg/mL (48.40 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.1000 mL 5.5002 mL 11.0005 mL5 mM 0.2200 mL 1.1000 mL 2.2001 mL10 mM 0.1100 mL 0.5500 mL 1.1000 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中

3、的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (2.75 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-C

4、D in saline)Solubility: 2.5 mg/mL (2.75 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oil1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (2.75 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Vinblastine sulfate種針對(duì)各種癌癥類(lèi)型的有細(xì)胞毒性的物堿。 長(zhǎng)春花堿可抑制微管的形成，抑制nAChR的IC50值為8.9 M。IC50 & Target I

5、C50: 8.9 M(nAChR) 1體外研究 Vinblastine does not depolymerize spindle microtubules, yet it powerfully blocks mitosis (for example, IC500.8 nM in HeLa cells) and cells die by apoptosis 2. In NB4 cells, vinblastine produces alteration of p53 andDNA fragmentation. Vinblastine treatment has an antiprolifera

6、tive effect via the induction of apoptosisproducing Bax/Bcl-2 imbalance. Vinblastine treatment suppresses NFB expression and depresses NFB-DNA binding activity while maintaining JNK activation that subsequently results in apoptotic responsethrough caspase-dependent pathway 3. Vinblastine is found to

7、 trigger apoptosis as evidenced by the loss ofmitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activationof caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase 4.體內(nèi)研究 Vinblastine is a widely used anticancer drug with undesired side effects.

8、Its conjugation with carriermolecules could be an efficient strategy to reduce these side effects 5.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Mutat Res Genet Toxicol Environ Mutagen. 2016 Sep 15;808:27-37. Int J Clin Exp Pathol. 2017;10(3):3033-3042.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. McKay DB,

9、et al. Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6.2. Pandya P, et al. Molecular recognition pattern of cytotoxic alkaloid vinblastine with multiple targets. J Mol Graph Model. 2014 Nov;54:1-9.3. Calvio E, et al. JNK and NFB depen

10、dence of apoptosis induced by vinblastine in human acute promyelocytic leukaemia cells. CellBiochem Funct. 2015 Jun;33(4):211-9.4. Selimovic D, et al. Vinblastine-induced apoptosis of melanoma cells is mediated by Ras homologous A protein (Rho A) via mitochondrialand non-mitochondrial-dependent mechanisms. Apoptosis. 2013 Aug;18(8):980-97.5. Bnczi Z, et al. Synthesis and in vitro antitumor effect of vinblastine derivative-oligoarginine conjugates. Bioconjug Chem. 2010 Nov17;21(11):1948-55.McePdfHeightCaution: Product has not been